The US Food and Drug Administration (FDA) has authorised surgical robotics company Medrobotics to market its Flex Robotic system for use in transoral procedures in the mouth and throat.
The Flex Robotic system is designed to provide an affordable, easy-to-use robot-assisted surgical platform for hospitals and surgeons seeking to offer minimally-invasive treatment options to the large number of patients.
Medrobotics president and CEO Dr Samuel Straface said: "The minimally invasive system enables surgical access and visualisation in hard-to-reach locations through a single site.
"Doctors can then complete procedures that might otherwise be difficult, or even impossible to perform due to inability to visualise or access the site."
Unlike legacy ‘line-of-sight’ approaches, the system features a flexible and robotic scope, which precisely moves through the body’s natural twists and turns, and becomes rigid to form a stable surgical platform, once the surgeon reaches the desired vantage point.
The on-board and high definition vision system is said to make it easy to see and operate with a range of flexible surgical instruments.
The wristed 3mm Flex Instruments helps surgeons to operate accurately in confined spaces.
Medrobotics Medical Advisory Board co-chair, Cleveland Clinic Head and Neck Institute professor and Emeritus chairman Dr Marshall Strome said: "The Flex Robotic System provides unparalleled access and visualisation of the oropharynx, hypopharynx and larynx.
"When used in combination with the highly adjustable Flex Retractor, surgeons can greatly extend their reach in challenging areas of the mouth and throat."
Having secured European CE mark clearance in March 2014, the company is currently initiating the commercial launch Flex Robotic system in the US hospitals.
Image: FDA has cleared Medrobotics Flex Robotic system for transoral procedures in the mouth and throat. Photo: courtesy of Business Wire.